

CLINICAL PRACTICE CHANGE

May 15, 2024

DIAGNOSTIC SERVICES

Endocrine Testing and Specialized Endocrinology Requisition Update

Date effective: May 27, 2024

Background Information: Effective May 27 2024, updated versions of R250-10-77 Specialized Endocrinology requisition will be implemented provincially to capture updates to endocrine tests. Use of the Specialized Endocrinology requisition is restricted to endocrinologists and few pre-approved physicians with other specialties as per SOP F10-50-45D. All other ordering providers should be using updated General Endocrinology Requisition (R250-10-76).

Summary of changes:

- Some test codes have been updated in the revised requisitions to reflect test repatriation and/or change in assay methodology.
- A new section for physicians to provide fasting instruction for patients has been added.
 Laboratory procedure for collection and reporting has not changed.
- Common Biochemistry/Hematology tests have been added to the requisition.
- 25-hydroxy vitamin D ordering is now available on endocrinology requisitions. Indications for ordering and signature are not required on this requisition.
- Oral Glucose Tolerance Test (OGTT 75g), C-telopeptide, Bone ALP and macroprolactin have been added to the requisition. Aldosterone Renin Ratio (ARR) is now an orderable test that will report aldosterone, renin mass and their ratio.
- Additional section for Miscellaneous tests was added including ordering for special investigations. Clinical Biochemist should be consulted for specimen details.
- Cortisol orders post dexamethasone suppression tests can be ordered separately to allow laboratories to add comment "post dexamethasone".
- A summary table with updated reference intervals for new and revised assays is attached. The effective date is May 27, 2024.
- Less common tests can be ordered under "Other Tests" section of the appropriate requisition.
 Please print legibly and consult Lab Information Manual (<u>Lab Information Manual (sbgh.mb.ca)</u>) for correct test names and requisitions.

References/Resources:

- See attached requisition with changes highlighted
- Please contact your site laboratory if you have any questions.



CLINICAL PRACTICE CHANGE

This requisition is	Speciali	zed Endocrin	ology Requisition		THIS SPACE FOR LAB USE ONLY	
restricted for use			d to pre-approved physicians	PLACE LIS LABEL HERE		
	Fields marked with * are mandatory and must b					
physicians only	Ordering Provider Information		Patient Information (prin	t or use a	addressograph)	
physicians only	*Last & Full First Name: Billing Code:		*Last/First Name: (per He	ealth Card		
	Inpatient Location:		* Date of Birth (dd/mm/			
	A TO CONTROL TO BE A TO CONTROL T					
	Ph #: Fax #:	*PHIN: Specify Province	or DND if	different		
	Copy Report To (if info missing, report may not be sent):		MRN: Encounter #:			
	Last & Full First Name: Ph #: Fax #:		Patient Ph #:			
	Facility Name/ Address:	Patient Address:				
	Last & Full First Name: Ph #: Fax #:					
	Facility Name/ Address:	Demographics verified via Health Card Armba		Chart/CR DOther		
Provide fasting		Patient Preparation	on Instructions (to be completed by ord	dering phy	ysician)	7
instructions to patient	⁶ Fast □ 8-12h □ Alternate time	h	☐ No (if not checked, assu	me non-	-fasting specimen)	
	Collec	tion Information (f	ields marked with + required by per			_
	◆Collection:	♦ Colle			Collection Date:	
	☐ Venipuncture ☐ Capillary ☐ Indwellin	g Line + Colle	ction Facility/Lab:		Collection Time:	
	# Serum tubes # Plass	ma tubes	Referring Lab: # of tubes sent _		Samples shipped frozen	
	Fasting information No Yes # c					
	Biochemistry/Hematology		ium & Bone		Miscellaneous	Լ
	☐ CBC (incl. differential)	CBC 🔲 Calciu			☐ Special Investigations MIS8	
	□ Sodium NA □ Albumin			AL ICA	Serum, no gel No. of tubes 1 2 3	Requests for special testing
					□SST 1□ 2□ 3□	(based on Clinical Biochemist consult)
	☐ Chloride ☐ Osmolality	CL ☐ PTH OS ☐ 25-hyd	de accessidado de la constancia de la co	PTHY VD25		
	☐ ALT	ALTR U Phosp		VD25	Collect on ice? Yes No	25(OH) vitamin D ordering
	□ CK	CK Magne		MG		
	☐ Creatinine & eGFR (if >18y outpatient)		peptide/CTx (osteoporosis treatment)	CTX		(maioanono ioi oraoning
	□ eGFR (order separately for inpatient only)	5050 -	Alkaline Phosphatase		Other tests:	not required)
	☐ Urea		urnover marker)°	MIS8	other tests.	
	Thyroid		Adrenal			
AM, PM or random	☐ TSH with reflex	TSH Cortis		COR	1	
cortisol order	☐ Free T4	FT4 Cortis	ol PM (3-5 pm) b	COR		
cortisor order	☐ Free T3		ol Random	COR		
Cortisol for DST	☐ Anti-TPO Ab (Thyroperoxidase Ab)		ol for Dexamethasone Suppression	COR		
Cortison for DST	☐ TRAb (TSH Receptor Ab)	TRAB Test (nb to add "post dexamethasone" comment)	COR		
	☐ Thyroglobulin (+ anti-Tg)		ight salivary cortisol offection devices: 2 3	SACO		
	Diabetes & Lipids ☐ Glucose (fasting, see § above)		(collect/ transport on ice,<60 min)	ACTH	_	
	Glucose (random)		productive, Fertility & Growth	ACIH	Bone ALP should only be used as a bone turnover	-
	☐ HbA1C	GYHB ☐ FSH	productive, Fertility & Growth	FSH		
	☐ OGTT 75g — Non-Pregnancy, fasting ⁶	GTT2 LH		LH	marker. Assay shows 20% cross-reactivity with hepatic	
	Lipid panel (see § above)	D DHEA	\$	DHAS	ALP.	
	(chol, TG, HDL-c, LDL-c, non-HDL-c)	LIPP Estrad		E2		
	☐ ApoB			PGN		
	☐ Insulin	APB Progesterone INS Prolactin (11 am -		PL		
	☐ C-peptide		roxyprogesterone (LC-MS/MS)	OH17		
attende of the second	☐ Anti-GAD 65 antibody			TST	^b If collected outside indicated time, do NOT reject	
Free & Bioavailable			sterone, Total, Bioavailable & Free	FTST	specimen, report as random cortisol.	
Anti Ingulia antibodu INAA			m, within 3 h of waking recommended)		Prolactin follows diurnal variation and levels are	
Testosterone	Hypertension	☐ Growt	h hormone	GH	higher for the first four hours after waking. Most	
Aldosterone Renin Ratio		ARR G IGF-1		IGF1	patients reach nadir levels by 11 am. Stress, exercise, medication (antihypertensive, antidepressant,	
is an orderable test.	☐ Aldosterone		juantitative)	HCGQ	antipsychotic, gastrointestinal), oral contraceptives,	
is an orderable test.	Renin	RENI			opioids, marijuana cause elevated prolactin.	

Shared health Soins communs Marktoba SAP # 356897

Approval Date: 27-MAY-202

R250-10-77 V06



CLINICAL PRACTICE CHANGE

Test Name	Units	Reference Intervals						
		Age	Gender	Low	Hi	Comment		
Aldosterone, plasma	pmol/L	0-<3y	M/F	83	3134			
		3 - <18y	M/F	144	677			
		>=18y	M/F	Comment		Upright: 61 - 978 pmol/L Supine: 32 - 654 pmol/L		
Aldosterone, 24h urine	nmol/day	<14y	M/F	M/F Comment		Reference intervals not established		
		>=14y	M/F	3	78			
Renin Direct	mIU/L	0 -<3y	M/F	7.7	172			
		3 - <18y	M/F	9.4	93			
		>=18y	M/F	1/F Comment		Upright: 4.4 - 46 mIU/L Supine: 2.8 - 40 mIU/L		
Aldosterone- Renin Ratio (ARR)	pmol/mIU	<18y	M/F	Со	mment	Thresholds have not been established in pediatric population		
		>=18y	M/F		<91	>90 pmol/L/µIU/mL strong positive 60-90 pmol/L/µIU/mL weak positive see 2020 Hypertension Canada Guidelines		
Growth Hormone	μg/L	All	M/F	Comment		Basal levels are not diagnostic. Stimulation or suppression tests are required for diagnosis of growth hormone related disorders.		
C-peptide	pmol/L	All	M/F	260	1390	Reference intervals are applicable to 12h fasting collection.		
ACTH	pmol/L	All	M/F	1	13	Reference intervals are applicable to morning (7h00-10h00) collection.		
IGF-1	μg/L	See <u>Lab Information Manual</u> for updated age and gender specific reference intervals.						